Abstract:Glioblastoma is the most frequent primary brain tumor in the adult, accounting for 53.8% of all gliomas (http://www.cbtrus.org), and it is one of the most deadly among all human tumors. Despite aggressive treatment at diagnosis, consisting of resection followed by radiation with concurrent and subsequent adjuvant chemotherapy with temozolomide, the tumor almost invariably recurs or progresses, with a patient median survival of 14.6 mo (1). The hallmark of glioblastoma that distinguishes it from all of the other glial tumors is microvascular proliferation in conjunction with necrosis. Therefore, treatment with antiangiogenic agents holds great promise to block the growth of this most vascularized tumor. The best-known antiangiogenic agents are inhibitors of VEGF-A, an indispensable angiogenic factor during developmental organogenesis and growth of numerous tumors. However, treatment with bevacizumab, a neutralizing antibody to VEGF-A, at relapse only confers transient benefit and a marginal increase in survival, indicating at tumor progression a VEGF-independent angiogenic mechanism of glioblastoma resistance (2). Several mechanisms have been implicated in angiogenesis. One is the sprouting of capillaries from preexisting blood vessels by endothelial proliferation (3). Another is the cooption of preexisting blood vessels by tumor cells, leading to expression of angiopoietin-2 by those vessels’ endothelial cells and tumor cell proliferation, followed later by involution of preexisting vessels in the core of the tumor, massive tumor cell apoptosis, organization of remaining tumor cells into pseudopalisading that resides around areas of necrosis, and tumor rescue at the margins by angiogenesis (4, 5). Expression of HIF-1α and up-regulation of VEGF-A have been identified in hypoxic perinecrotic pseudopalisading tumor cells (4–6). Hypoxia induces elevated levels of VEGF-A (6) and VEGF-A receptors that appear up-regulated in tumor endothelial cells but not in normal brain (7). Another mechanism is the release of angiogenic factors by the tumor that recruit bone marrow-derived …

Vasculostatin Inhibits Intracranial Glioma Growth and Negatively RegulatesIn Vivoangiogenesis Through a CD36-Dependent Mechanism

Supplementary Note from Vasculostatin Inhibits Intracranial Glioma Growth and Negatively Regulates <i>In vivo</i> Angiogenesis through a CD36-Dependent Mechanism

Supplementary Figure 2 from Vasculostatin Inhibits Intracranial Glioma Growth and Negatively Regulates <i>in Vivo</i> Angiogenesis Through a CD36-Dependent Mechanism

Abstract 3433: A furin/MMP-14 signaling cascade processes BAI1 into a novel secreted anti-angiogenic and anti-tumorigenic factor, Vasculostatin-40 (Vstat40)

Therapeutic Application of Brain-Specific Angiogenesis Inhibitor 1 for Cancer Therapy

Suppression of intracranial human glioma growth after intramuscular administration of an adeno-associated viral vector expressing angiostatin.

A Target For Antiangiogenic Therapy: Vascular Endothelium Derived From Glioblastoma

Downregulation of Astrocyte Elevated Gene-1 Expression Combined with All-Trans Retinoic Acid Inhibits Development of Vasculogenic Mimicry and Angiogenesis in Glioma.

Human Tumstatin and Human Endostatin Exhibit Distinct Antiangiogenic Activities Mediated by Αvβ3 and Α5β1 Integrins

The effection and the mechanism of alphastatin supressing the vasculogenic mimicry formation of glioma

Enhanced expression of Vastatin inhibits angiogenesis and prolongs survival in murine orthotopic glioblastoma model

Decrease Of Endogenous Vascular Endothelial Growth Factor May Not Affect Glioma Cell Proliferation And Invasion

A Gene Therapy for Cancer Based on the Angiogenesis Inhibitor, Vasostatin.

Tumstatin Transfected into Human Glioma Cell Line U251 Represses Tumor Growth by Inhibiting Angiogenesis

Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate

Vasculogenic Mimicry–potential Target for Glioblastoma Therapy: an in Vitro and in Vivo Study

Single Administration of AAV Vector in Muscle Resulted in a High-Level and Prolonged Secretion of Angiostatin into Blood

Galunisertib Inhibits Glioma Vasculogenic Mimicry Formation Induced by Astrocytes

Inhibition Of Tumor-Induced Edema By Antisense Vegf Is Mediated By Suppressive Vesiculo-Vacuolar Organelles (Vvo) Formation

Low- and high-grade glioma-associated vascular cells differentially regulate tumor growth

Transcriptional Profiling of Human Glioblastoma Vessels Indicates a Key Role of VEGF‐A and TGFβ2 in Vascular Abnormalization